Author

C. Morisseau

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:differential expression· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

B. D. Hammock· 2 shared J. Yang· 2 shared A. Takamura· 1 shared C. Escolano· 1 shared C. Galdeano· 1 shared C. Grinyan-Ferre· 1 shared C. Sanfeliu· 1 shared D. Li· 1 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

B. D. Hammock

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BiochemistrybioRxivPreprintJan 20, 2022

PROTAC-mediated selective degradation of cytosolic soluble epoxide hydrolase enhances ER-stress reduction

Y. Wang, C. Morisseau, A. Takamura…·S. Kitamura

This paper develops first-in-class PROTACs that selectively degrade cytosolic sEH, reducing ER stress more effectively than sEH inhibitors.

DOI 10.1101/2022.01.20.477134

humanproteomics

Pharmacology & ToxicologybioRxivApr 10, 2019

Pharmacological inhibition of soluble epoxide hydrolase as a new therapy for Alzheimer’s Disease

C. Grinyan-Ferre, S. Codony, E. Pujol…·C. Galdeano

This study investigates the therapeutic potential of sEH inhibition in Alzheimer’s Disease, showing reduced cognitive impairment, tau pathology, and amyloid plaques in animal models.

DOI 10.1007/s13311-020-00854-1

mouseexperimental assay